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Evidence-based prescribing: Combining network meta-analysis and multi-criteria 
decision analysis to choose among multiple drugs 
The challenging nature of evidence-based decision-making  
“What is the drug of choice for condition x?” is among the most commonly asked questions in primary 
care.1 Reflecting the complexity of prescribing decisions, answering this question requires a difficult 
trade-off between the benefits and harms of multiple drugs for a given condition.  
The principles of evidence-based medicine suggest that prescribing decisions should be guided by an 
objective benchmark, namely scientific evidence.2 Such evidence is particularly important when 
choosing a first-line treatment among multiple alternatives. Unfortunately, existing clinical evidence on 
benefits and harms is rarely adequate to inform prescribing decisions. A randomized controlled trial 
comparing all relevant drugs would provide such information. However, clinical trials are often designed 
for regulatory purposes and therefore include selective patient populations and do not include all 
available comparator drugs.3,4 In order to obtain insight into the comparative benefits and harms of 
multiple drugs, prescribers turn to summaries of evidence to discern the most promising drugs from 
their less effective comparators.  
Recent methods used to synthesize existing evidence provide much-needed information on the 
comparative benefits and harms of multiple drugs. Network meta-analysis is one such method that 
allows for the combination of direct and indirect evidence from randomized trials, facilitating the 
comparison of all relevant drugs even when they are not directly compared to each other in clinical 
trials.5 The recent surge in the number of network meta-analyses in the general medical literature is a 
testament to the increasing need for comparative evidence in prescribing decisions.6 Even when 
comparative evidence from network meta-analyses exists, however, making sense of it remains a 
challenge. In particular, prescribers and patients often struggle to weigh the relative benefits and harms 
of multiple alternatives.  
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In this proof-of-concept study, we discuss the important yet challenging role of comparative clinical 
evidence in guiding prescribing decisions in clinical practice. Using a recent systematic review and 
network meta-analysis of statins as an example, we highlight the need to adopt a more formal 
framework to help prescribers and patients in identifying a first line drug among multiple alternatives. 
We call for combining network meta-analysis methods with decision analytic approaches such as multi-
criteria decision analysis to encourage and facilitate shared decision-making between prescribers and 
patients.  
Synthesizing existing evidence: Insights from the quarter-century history of statins 
Statins are among the most widely prescribed classes of drugs, used to prolong survival by reducing the 
risk of heart attacks and strokes.7-10 In addition to their benefits, statins are generally safe with rare 
adverse events.11,12 Although a large number of randomized controlled trials compared statins head-to-
head, until recently, findings of these active-comparator trials were neither systematically identified nor 
combined with the findings of placebo-controlled trials. Previous meta-analyses were pairwise in nature, 
which, by definition, compared two alternatives at a time. Even previous attempts at analyzing the 
comparative benefits and harms of multiple statins did not identify and include active-comparator 
trials.13-17 Over the past 25 years, there has not been any comprehensive review of the existing literature 
evaluating whether individual statins (irrespective of their cholesterol-lowering effects) are different in 
terms of their benefit and harm profiles. Despite the absence of comparative evidence demonstrating its 
superiority to other statins in terms of its benefit and harm profile, utilization rates of five statins trailed 
behind those of atorvastatin (Lipitor®)18 making it the best-selling medication in history.19  
A recent review of the clinical trial literature20 – set out to help prescribers in selecting a first-line statin 
– highlighted the essential role of network meta-analysis methods in synthesizing the existing evidence 
on statins. First, network meta-analysis methods allowed for the combination of both placebo-controlled 
and active-comparator trials, incorporating the entirety of relevant evidence. Second, these methods 
allowed for ranking individual statins with comparable LDL cholesterol lowering effects on the basis of 
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clinically meaningful benefit and harm outcomes. Similarity or interchangeability of statin doses was 
established by a statistical analysis of LDL cholesterol lowering effects at different doses.21 Long-term 
benefit outcomes included all-cause mortality, major coronary events, and major cerebrovascular events. 
Short- to intermediate-term tolerability and harm outcomes were discontinuations due to adverse 
events, myalgia, and creatine kinase and hepatic enzyme elevations.  
Insofar as this review provided much-needed answers regarding the comparative effects of individual 
statins, it also highlighted the challenging nature of making sense of the existing evidence on harms and 
benefits of multiple alternatives, and their trade-offs. First, this comprehensive review including almost 
200 clinical trials did not conclusively distinguish between individual statins. Perhaps unsurprisingly, 
individual statins differed in terms of their comparative effects on benefit and harm outcomes 
(Supplemental Table). Based on the available evidence on major coronary events, for example, 
fluvastatin had the most favorable efficacy profile, followed by atorvastatin (Figure 1).22 In terms of 
adverse outcomes, pravastatin had the most favorable tolerability profile, i.e., the highest probability of 
ranking best in terms of its effect on discontinuations due to adverse events.23  
Second, considering additional benefit and harm outcomes further complicated the decision around 
which statin should be preferred as the first drug of choice. Simvastatin ranked higher than other statins 
in reducing the risk of all-cause mortality and major cerebrovascular events.24 However, it was 
associated with relatively high rates of creatine kinase elevations, indicating potential muscle damage. 
While atorvastatin ranked high in terms of major coronary outcomes, it had a high probability of ranking 
last in terms of hepatic enzyme elevations, which indicate hepatotoxicity.  
In many ways, this review underscored the challenges facing prescribers who are charged with not only 
making sense of a disparate set of findings, but also basing their prescribing decisions on the existing 
evidence. Complicating matters further, there was no clear way to identify the winner among statins, 
leaving it up to the prescriber to decide whether – and to what extent – long-term clinical benefits 
outweighed more intermediate-term harms for any given statin.  
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Making sense of existing evidence using multi-criteria decision analysis 
The complexity of prescription drug therapy stems from the difficulty in making trade-offs between the 
benefits and harms of two or more options. Frustrating for prescribers, there is a lack of a conceptual 
framework with regard to balancing the benefits and harms of prescription drugs. A more formal 
approach is needed to help prescribers and patients in identifying a first line drug among multiple 
alternatives. One such approach is multi-criteria decision analysis,25 which is a formal framework for 
analysis of complex decision problems involving trade-offs between multiple outcomes.26 An attractive 
feature of multi-criteria decision analysis is that it applies qualitative or quantitative preferences on 
different outcomes, allowing for a transparent judgment on their relative importance.27-29 
When applied to prescription drug therapy, multi-criteria decision analysis consists of four key 
elements.26 First is choosing the alternatives to be appraised (e.g., multiple drugs in a given class). 
Second is deciding on the criteria against which the alternatives are appraised (e.g., different benefit and 
harm outcomes). Third is estimating the comparative performance of each alternative on each criterion 
(e.g., comparative effects of each drug on different benefit and harm outcomes). Finally, fourth is 
determining the criteria weights that indicate the relative importance of each criterion as compared to 
others (e.g., preferences about the relative importance of different benefit and harm outcomes).  
Recently, multi-criteria decision analysis was considered alongside network meta-analysis, thereby 
greatly improving the interpretability of existing evidence by making explicit the difficult trade-offs 
between outcomes.30 To illustrate the promise of this combined approach, we revisited the recent 
systematic review of statins and combined information on multiple outcomes using qualitative 
preference statements in a proof-of-concept study (see below for the methods of combining network 
meta-analysis and multi-criteria decision-analysis). When combining the evidence on multiple 
outcomes, we adopted simple preference statements about the relative importance of different 
outcomes and considered the effect of statins on preventing mortality to be more important than either 
major coronary or cerebrovascular events, which were in turn more important than any one of the 
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tolerability or harm outcomes. This assumption was justified in the case of statins where side effects are 
generally not severe,31 and clinical practice guidelines emphasize total mortality as more important than 
non-fatal coronary and cerebrovascular outcomes.32,33  
Methods of combining network meta-analysis and multi-criteria decision analysis 
Applying weights to different criteria, multi-criteria decision analysis allows trade-offs between 
different outcomes of interest. To determine the weights, the decision maker is first asked to rank the 
importance of improving each outcome from its worst possible value to its best – such that the weight 
for outcome B (e.g., major coronary events) must be greater than that for outcome A (e.g., all-cause 
mortality). Various elicitation methods can be applied to make this information more precise, or even 
assign fixed values to the weights. Since the weights are subsequently used to compare specific numeric 
values for different outcomes, it is important to take into account the scales on which the outcomes have 
been measured when constructing the preference information.  
For the recent systematic review of the statin trials, we took into account the evidence for the previously 
assessed benefit and harm outcomes, as obtained from separate network meta-analyses. To enable a 
meaningful comparison between the outcomes, we calculated absolute risks by multiplying the odds 
ratios obtained from network meta-analysis with the average odds of events across the control arms of 
included trials, thereby placing all outcomes on the same scale.30,34 We then applied a structured benefit-
risk model that allows evidence on multiple outcomes to be combined using qualitative preference 
statements.25,30,35 This benefit-risk model took into account the probability distributions of all outcomes 
of interest and quantified the uncertainty around a decision, while keeping outcome measurements and 
value judgments clearly separated.25  
Specifically, we sampled from the posteriors for the absolute risk on each outcome, which were 
translated to a partial utility between 0 and 1 (where 1 was best possible and 0 the worst possible 
value) for all alternative treatments and for all outcomes. For each such sample, there was a 
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corresponding set of criteria weights (preferences), which summed to one. Instead of using fixed criteria 
weights, we sampled them from all possible weights that were compatible with the ordinal preference 
information. The utility for each alternative statin was the weighted sum of the partial utilities. The 
structured benefit-risk model was based on 10,000 iterations to create a sample from the posterior 
distribution for the utilities, which was subsequently used to generate Figure 2 (to rank individual 
statins).  
Many multi-criteria decision analysis methods require exact values to be assigned to the weights. The 
method we applied handled qualitative preference statements by randomly sampling from all 
weightings compatible with the preference information.29,35 The final ranking thus incorporated two 
sources of uncertainty: uncertainty about the effects of the treatments, and uncertainty due to the 
imprecision of the preference information. In some cases, the uncertainty due to imprecision of the 
preferences can be substantial, but in this case our analysis showed that most of the uncertainty in the 
ranking was due to uncertainty of the treatment effects. 
Ranking individual statins using decision analytic approaches 
Figure 2 shows the distribution of ranking probabilities. In this figure different colors show different 
ranks, with darker colors showing better ranks. Using this figure, a decision-maker would want to 
choose the statin with the highest probability of best ranks (i.e., highest distribution of dark colors). 
According to Figure 2, fluvastatin has a considerable probability of both being the best (41%) and worst 
(12%) statin (based on the combination of benefits and harms), highlighting the uncertainty in its 
evidence base. In contrast, both simvastatin and atorvastatin have a high probability of better ranks, 
with a negligible probability of ranking worst.  
One way of interpreting the existing evidence, then, would be to conclude that atorvastatin and 
simvastatin have the most favorable benefit and harm profiles. Of course, this interpretation is 
dependent on our set of qualitative preferences on the relative importance of different outcomes 
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(assuming that the effect of statins on preventing mortality is important than either major coronary or 
cerebrovascular events, which are in turn more important than any one of the tolerability or harm 
outcomes). Others may consider tolerability and harm outcomes to be equally or even more important 
than benefit outcomes. Indeed, differing preferences regarding the relative importance of different 
outcomes should be taken into account in prescribing decisions. One of the advantages of combining 
network meta-analysis with multi-criteria decision analysis is that this combined approach allows 
prescribers and patients to weight different outcomes differently and see how drug rankings change 
accordingly. Another key advantage of this approach is that it is patient-centered: Patient preferences 
can be used to determine the relative importance of different benefit and harm outcomes. This is 
important as individual patients differ in terms of their preferences for different outcomes.36 For 
example, some patients may even prefer death to severe disability following stroke. Considering patient 
values would facilitate shared decision-making between patients and prescribers in choosing among 
multiple drugs.  
Evidence-based prescribing: are we there yet? 
Although the methodological standards for conducting and reporting systematic reviews and meta-
analyses have improved substantially over the last two decades, they offer little guidance for making 
trade-offs between multiple benefit and harm outcomes. We envision a future where summaries of 
existing clinical literature are frequently combined with patient preferences, and considered alongside 
the knowledge and clinical expertise of prescribers when making prescribing decisions. For example this 
might take the form of a patient decision support tool that relies on the findings of published network 
meta-analyses, which can then be considered in light of patient preferences. If presented in an accessible, 
easy-to-use, and understandable format, patients could, for example, work through the evidence-based 
information in their own time, and then discuss with their clinician before finalizing their decision. 
Several patient decision aid tools already exist that aim to facilitate shared decision-making.37 Existing 
evidence suggests that using such tools improve patients’ knowledge; manage their expectations 
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regarding drug therapy, and allow patients to make decisions that are more consistent with their 
informed values.38  
Such a future rests on the assumption that existing evidence, as well as its reviews and syntheses, are 
valid and reliable. As with any other method, network meta-analysis is not without its limitations, and 
these should be carefully investigated and addressed. Although the validity of the statistical methods 
underlying network meta-analysis is widely accepted,39,40 there is concern about the combination of 
direct and indirect evidence post-hoc from published data. The validity of network meta-analysis 
depends on the distribution of relative treatment effect modifiers across comparisons (e.g., age, baseline 
disease severity).41 An imbalance in the distribution of relative treatment effect modifiers across 
treatment comparisons can bias the results of network meta-analysis, and should be explored using 
meta-regressions and subgroup analyses.42 To ensure valid findings, both pairwise and network meta-
analyses should be reserved for sets of trials conducted in relatively homogeneous clinical populations. 
Selective publication of randomized trials with favorable findings, often termed publication bias, may 
also pose a threat to the validity of evidence syntheses.43  
Similarly, more research is needed on the application of multi-criteria decision analysis in health care 
decisions. First, it is important to consider how to gauge patient preferences in clinical practice settings 
and beyond. An important question to consider is: which preference elicitation techniques would work 
best for different populations of patients? Second, whether existing utility instruments, such as the EQ-
5D can be used to rank different outcomes using population-level preferences should be investigated. 
Although existing utility measures are suitable for calculating quality-adjusted life-years in the context 
of cost-effectiveness analysis, they may not be particularly sensitive to individual patient preferences 
and trade-offs between different outcomes. In addition, seeking individual patient input (as opposed to 
population-level utilities) would be desirable because patient preferences are intrinsically different at 
the individual level, and vary over time due to external factors.44  
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A related challenge is the “granularity” and applicability of the existing evidence. Generalizing the 
findings of randomized controlled trials to individual patients seen in clinical practice remains a 
challenge. Although the findings of randomized controlled trials – or their syntheses in meta-analyses – 
may be particularly helpful for the “average” patient or population, patients often do not respond 
uniformly to therapies. In addition, randomized controlled trials are often short-term; do not report 
important harm outcomes; and include selective patient populations, which may differ greatly in terms 
of their age, gender, and co-morbidity profiles from those seen in clinical practice.45 Despite much 
enthusiasm for tailoring decisions for individual patients, existing clinical evidence is not detailed 
enough to individualize treatment options.  
In the case of statins, despite their quarter-century history, there is still inadequate evidence for a 
meaningful comparison of individual drugs in primary and secondary prevention. For instance, there is 
no available all-cause mortality data on simvastatin among individuals without established coronary 
heart disease; no data on the effect of fluvastatin and simvastatin on major coronary events in primary 
prevention; and no data on the effect of fluvastatin and rosuvastatin on major coronary events in 
secondary prevention. In addition, there is a paucity of information on populations that are most likely 
to receive statins, such as those 75 years of age and older that are eligible for statin therapy for the 
secondary prevention of coronary heart disease.22,23  
Given the absence of adequate effectiveness data on sub-groups by racial, ethnic, genetic, and co-
morbidity profiles of patients, a synthesis of all randomized controlled trials of statins constitutes the 
current best evidence on the comparative benefits and harms of drugs, and should form the basis of 
prescribing decisions – alongside clinical expertise and patient preferences – about the care of 
individual patients.  
Conclusion 
After two decades of “evidence-based medicine” incorporating scientific evidence into prescribing 
decisions remains challenging. The combination of network meta-analysis with multi-criteria decision 
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analysis holds the promise to introduce more transparency to the decision-making process and 
potentially increase the relevance and informative value of existing evidence for prescribing decisions. 
This combined approach would have important advantages. First, prescribing decisions would take into 
account multiple benefit and harm outcomes on all relevant alternatives. Second, such an approach 
would make explicit the qualitative preferences and trade-offs between these outcomes. Third, patient 
values and choices can be considered alongside the knowledge and expertise of prescribers, making 
shared decision-making a reality in clinical practice. Taken together, this combined approach has the 
potential to improve prescribing decisions.  
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Figure Legends 
Figure 1 – Distribution of ranking probabilities for individual statins.  
Figure 2 – Comparative benefit-harm profiles of individual statins on the basis of placebo-controlled 
and active-comparator trials.  
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Figure 1: Distribution of ranking probabilities for individual statins. Ranking for each treatment indicates the probability of being the best treatment, the 
second best, the third best, and so on. For simplicity, this figures provides the relative ranking probabilities for only two outcomes. Tolerability depicts 
discontinuations due to adverse events whereas efficacy refers to primary and secondary prevention of major coronary events. Based on this figure, fluvastatin 
has the most favorable efficacy profile, followed by atorvastatin. In terms of adverse outcomes, pravastatin has the most favorable tolerability profile.  
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Figure 2: Comparative benefit-harm profiles of individual statins on the basis of placebo-
controlled and active-comparator trials. This figure combines the overall benefit (all-cause 
mortality, major coronary events, and major cerebrovascular events) and harm 
(discontinuations due to adverse events, myalgia, transaminase elevation, and creatine kinase 
elevation) outcomes for each statin, estimated based on probability distributions for absolute 
effect sizes. The figure shows the distribution of ranking probabilities for both benefit and harm 
outcomes, taking into account the qualitative preference statements about the relative 
importance of different outcomes (all-cause mortality assumed to be more important than 
either major coronary or cerebrovascular events, which were in turn assumed to be more 
important than any of the harm outcomes). Based on this figure, fluvastatin has a considerable 
probability of both being the best (41%) and worst (12%) statin, highlighting the uncertainty in 
its evidence base. In contrast, both simvastatin and atorvastatin have a high probability of better 
ranks, with a negligible probability of ranking worst. 
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